Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASLN NASDAQ:EGRX NASDAQ:GELS NASDAQ:SNYR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASLNASLAN Pharmaceuticals$0.60$0.60$0.48▼$25.44$1.23M1.4122,322 shsN/AEGRXEagle Pharmaceuticals$0.38$0.29$0.00▼$3.87$4.87M0.833,751 shs55 shsGELSGelteq$0.44-3.4%$0.67$0.39▼$3.51$4.67M0.06172,458 shs67,104 shsSNYRSynergy CHC$0.29+4.4%$0.78$0.27▼$4.00$4.27M-0.26936,873 shs566,512 shsThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASLNASLAN Pharmaceuticals0.00%0.00%0.00%0.00%0.00%EGRXEagle Pharmaceuticals0.00%-1.32%+7.14%+50.00%-80.67%GELSGelteq-3.43%-7.47%-37.74%-45.53%-70.15%SNYRSynergy CHC+4.37%-26.58%-47.86%-82.41%-85.22%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASLNASLAN Pharmaceuticals$0.60$0.60$0.48▼$25.44$1.23M1.4122,322 shsN/AEGRXEagle Pharmaceuticals$0.38$0.29$0.00▼$3.87$4.87M0.833,751 shs55 shsGELSGelteq$0.44-3.4%$0.67$0.39▼$3.51$4.67M0.06172,458 shs67,104 shsSNYRSynergy CHC$0.29+4.4%$0.78$0.27▼$4.00$4.27M-0.26936,873 shs566,512 shsThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASLNASLAN Pharmaceuticals0.00%0.00%0.00%0.00%0.00%EGRXEagle Pharmaceuticals0.00%-1.32%+7.14%+50.00%-80.67%GELSGelteq-3.43%-7.47%-37.74%-45.53%-70.15%SNYRSynergy CHC+4.37%-26.58%-47.86%-82.41%-85.22%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASLNASLAN Pharmaceuticals 0.00N/AN/AN/AEGRXEagle Pharmaceuticals 0.00N/AN/AN/AGELSGelteq 1.00SellN/AN/ASNYRSynergy CHC 2.33Hold$6.252,079.98% UpsideCurrent Analyst Ratings BreakdownLatest ASLN, EGRX, SNYR, and GELS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2026GELSGelteq Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/22/2026GELSGelteq Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/14/2026SNYRSynergy CHC Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$5.00 ➝ $5.504/10/2026SNYRSynergy CHC Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D-)3/27/2026SNYRSynergy CHC Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)(Data available from 5/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASLNASLAN Pharmaceuticals$12M0.10N/AN/A($6.50) per share-0.09EGRXEagle Pharmaceuticals$257.55M0.02$0.94 per share0.40N/A∞GELSGelteq$110K42.43N/AN/A$1.08 per share0.40SNYRSynergy CHC$30.38M0.14N/AN/A($2.06) per share-0.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASLNASLAN Pharmaceuticals-$44.22M-$21.92N/AN/AN/AN/A-8,454.87%-121.60%N/AEGRXEagle Pharmaceuticals$35.64M$1.180.32N/AN/AN/AN/AN/AN/AGELSGelteq-$4.30MN/AN/AN/AN/AN/AN/AN/AN/ASNYRSynergy CHC-$12.34M-$1.07N/A1.19N/A-60.02%-19.51%-25.63%N/ALatest ASLN, EGRX, SNYR, and GELS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026SNYRSynergy CHC$0.03-$0.23-$0.26-$0.23N/A$5.49 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthASLNASLAN PharmaceuticalsN/AN/AN/AN/AN/AEGRXEagle PharmaceuticalsN/AN/AN/AN/AN/AGELSGelteqN/AN/AN/AN/AN/ASNYRSynergy CHCN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASLNASLAN PharmaceuticalsN/A1.051.05EGRXEagle PharmaceuticalsN/AN/AN/AGELSGelteqN/AN/AN/ASNYRSynergy CHCN/A1.220.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASLNASLAN Pharmaceuticals58.82%EGRXEagle Pharmaceuticals85.36%GELSGelteqN/ASNYRSynergy CHCN/AInsider OwnershipCompanyInsider OwnershipASLNASLAN Pharmaceuticals4.69%EGRXEagle Pharmaceuticals28.90%GELSGelteqN/ASNYRSynergy CHC56.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASLNASLAN Pharmaceuticals302.04 million1.95 millionNo DataEGRXEagle Pharmaceuticals10012.99 million9.23 millionNo DataGELSGelteqN/A10.71 millionN/AN/ASNYRSynergy CHC4014.90 million6.47 millionN/AASLN, EGRX, SNYR, and GELS HeadlinesRecent News About These CompaniesSynergy Hesitates on Quarterly NumbersMay 15 at 4:13 AM | baystreet.caSynergy CHC Corp. (SNYR) Reports Q1 Loss, Misses Revenue EstimatesMay 14 at 10:25 AM | zacks.comSynergy CHC Corp. Reports First Quarter 2026 Financial ResultsMay 14 at 8:00 AM | globenewswire.comSynergy CHC Establishes Equity Line Financing AgreementMay 11, 2026 | tipranks.comSynergy CHC Corp. Stock Short Interest Rises to 35.83%May 5, 2026 | quiverquant.comQSynergy CHC Corp. (NASDAQ:SNYR) Short Interest Up 3,525.7% in AprilApril 25, 2026 | defenseworld.netDSynergy CHC shares surge nearly 100% in after-hours trading: What's going on?April 14, 2026 | msn.comSynergy CHC Corp. (NASDAQ:SNYR) Q4 2025 Earnings Call TranscriptApril 3, 2026 | insidermonkey.comSynergy CHC Corp (SNYR) Q4 2025 Earnings Call Highlights: Navigating Challenges and Seizing ...April 1, 2026 | finance.yahoo.comSynergy CHC Corp. (SNYR) Q4 2025 Earnings Call TranscriptApril 1, 2026 | seekingalpha.comSynergy CHC delays annual Form 10-K filingApril 1, 2026 | tipranks.comSynergy CHC Corp. Reports Fourth Quarter and Full Year 2025 Financial ResultsApril 1, 2026 | globenewswire.comSynergy CHC Corp. Announces New Release Date for Fourth Quarter and Full Year 2025 Financial ResultsMarch 30, 2026 | quiverquant.comQSynergy CHC Corp. Announces Date Change of Fourth Quarter and Full Year 2025 Earnings and Conference CallMarch 30, 2026 | globenewswire.comSynergy CHC (NASDAQ:SNYR) versus Colgate-Palmolive (NYSE:CL) Critical ReviewMarch 29, 2026 | defenseworld.netDSynergy CHC Corp. Announces Fourth Quarter and Full Year 2025 Earnings and Conference Call InformationMarch 17, 2026 | globenewswire.comSynergy CHC Brand License Terminated, Eyes Direct ExpansionMarch 3, 2026 | tipranks.comAscendiant Capital initiates coverage of Synergy CHC (SNYR) with buy recommendationFebruary 3, 2026 | msn.comSynergy CHC Corp. (NASDAQ: SNYR) Expands FOCUSfactor® Functional Beverage Distribution Across Canada Through Walmart Canada and McKesson CanadaJanuary 27, 2026 | globenewswire.comNew to The Street Airs Tonight on Bloomberg Television – Show No. 712 Sponsored Programming Spotlighting Public and Private Market InnovatorsJanuary 3, 2026 | desmoinesregister.comDNew MarketBeat Followers Over TimeMedia Sentiment Over TimeASLN, EGRX, SNYR, and GELS Company DescriptionsASLAN Pharmaceuticals NASDAQ:ASLN$0.60 0.00 (0.00%) As of 05/15/2026ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.Eagle Pharmaceuticals NASDAQ:EGRX$0.38 0.00 (0.00%) As of 05/15/2026Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.Gelteq NASDAQ:GELS$0.44 -0.02 (-3.43%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$0.43 -0.01 (-1.79%) As of 05/15/2026 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Gelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc. is based in NEW YORK.Synergy CHC NASDAQ:SNYR$0.29 +0.01 (+4.37%) As of 05/15/2026 04:00 PM EasternSynergy CHC Corp. engages in the marketing and distribution of branded health and wellness products. The company was founded on December 29, 2010 and is headquartered in Westbrook, ME. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Peloton Stock Gives Back Gains After Upbeat Earnings Report MarketBeat Week in Review – 05/11 - 05/15 Datavalut Gains Traction: 5 Reasons to Sell Now TMC Stock: Why This Pre-Revenue Miner Is Worth Watching Alphabet's Googlebook Brings Gemini AI to PC Hardware Viking Sails to All-Time Highs—Fundamentals Signal More to Come YETI Rallies After Earnings Beat and Raised Outlook Aeluma's Post-Earnings Dip Creates a Buying Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
